Responses
Regular and young investigator award abstracts
Clinical trials in progress
363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
Compose a Response to This Article
Other responses
No responses have been published for this article.
